FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

| Vashington, | D.C. 20549 |
|-------------|------------|
|-------------|------------|

| STATEMENT | OF CH | HANGES | IN E | BENEFI | CIAL | OWNE | RSHIP |
|-----------|-------|--------|------|--------|------|------|-------|
| | | | | | | | |

| OMB APPROVAL | | | | | | | | | |
|---------------------|-----------|--|--|--|--|--|--|--|--|
| OMB Number: | 3235-0287 | | | | | | | | |
| Estimated average b | urden | | | | | | | | |
| hours per response: | 0.5 | | | | | | | | |

S Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

| | | | | | ui seci | 1011 30(11) | JI LITE | invesiment c | Joinparty Act | 01 1940 | | | | | | | |
|---|---|--|---|-----------------|---|--|---------|---|---|--|--------------------------------------|---|--|-------|--|---------------------------------------|--|
| 1. Name and Address of Reporting Person* Powchik Peter | | | | | 2. Issuer Name and Ticker or Trading Symbol Vaxxinity, Inc. [VAXX] | | | | | | (Che | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner | | | | | |
| (Last) | (F | irst) | (Middle) | | 3. Date of Earliest Transaction (Month/Day/Year) 10/01/2023 | | | | | | | Officer (give title below) | | | Other (specify below) | | |
| 505 ODYSSEY WAY | | | | 4 | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | 6. Individual or Joint/Group Filing (Check Applicable Line) | | | | | |
| (Street) MERRIT | H | FL 32953 | | | | | | | | | | X Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | | |
| (City) | (S | tate) | (Zip) | F | Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. | | | | | | | | | | | | |
| | | Ta | ble I - Non- | Derivati | ve Se | curities | s Ac | quired, D | isposed c | of, or Be | neficially | / Owned | | | | | |
| Date | | | 2. Transacti Date Month/Day/ | Execution Date, | | 3. 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1 | | ed (A) or str. 3, 4 and | 5. Amour Securities Beneficia Owned Fo | s Form: (D) or ollowing (I) (Ins | | : Direct I Indirect E str. 4) | 7. Nature of Indirect Beneficial Ownership | | | | |
| | | | | | | | Code V | Amount | (A) o (D) | r Price | Reported Transacti (Instr. 3 a | ion(s) | | | Instr. 4) | | |
| | | | Table II - D (e | | | | | uired, Dis , options | • | • | , | Owned | | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | Code | action (Instr. | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | 6. Date Exer Expiration D (Month/Day/ | ate | of Securities | | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported | | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | Beneficial Ownership (Instr. 4) | |
| | | | | Code | v | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | Transaction(: (Instr. 4) | ontoj | | | |
| Stock | | | | | | | | | | Cl A | | | | | | | |

Explanation of Responses:

(right to buy)

1. These options were granted following the Reporting Person joining the Issuer's leadership team as Executive Vice President, Global Scientific Director, effective October 1, 2023, while remaining a member of the Issuer's board of directors.

(2)

(3)

 $2. \ These \ options \ vest \ in \ 12 \ equal \ monthly \ installments \ beginning \ on \ October \ 1, \ 2023.$

10/02/2023(1)

3. These stock options shall expire upon the earlier of (i) the tenth anniversary of the grant date, and (ii) three months after the date the Reporting Person ceases to be a director, officer, employee or consultant of the Issuer or one of its affiliates

/s/ Rene Paula Molina,

10/11/2023 attorney-in-fact for Peter

159,744

D

Powchik

common

stock

** Signature of Reporting Person Date

159,744

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.